MDS: New Drug Promising in Early Parkinson's Disease
In phase II trial, pardoprunox group shows improvement in motor score compared with placebo
WEDNESDAY, June 25 (HealthDay News) -- Pardoprunox can reduce symptoms in patients with early-stage Parkinson's disease, according to the results of a phase II trial presented at the Movement Disorder Society's 12th International Congress of Parkinson's Disease and Movement Disorders, held June 22 to 26 in Chicago.
Juliana Bronzova, of Weesp, the Netherlands, and colleagues analyzed data from 139 patients who were randomized to placebo or pardoprunox, which is a serotonin 5-HT1A agonist and partial dopamine D2 and D3 agonist, and may act as a dopamine stabilizer. Subjects underwent a titration phase of two to six weeks, during which the dose was titrated to 9 to 45 milligrams daily, followed by a three-week fixed maintenance period.
Patients in the treatment group showed significant improvement in the Unified Parkinson's Disease Rating Scale part III motor score (-7.3 points compared to -3.0 points for the placebo group at endpoint). The most commonly reported adverse events in the treatment group included nausea, dizziness and headache.
"These data show that pardoprunox was well-tolerated, and achieved significant reductions in symptomatology by the end of the titration period (average of 24 days), maintained during the three-week maintenance phase. The results of this phase II clinical trial indicate that pardoprunox monotherapy may provide significant clinical benefits to patients with early-stage Parkinson's disease," the authors conclude.